86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details


臨床試験数 : 1,181 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04207593
(ClinicalTrials.gov)
April 1, 201917/12/2019The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With HypoxemiaProspective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPHOxygen Deficiency;Pulmonary Arterial Hypertension;CTEPHDrug: OxygenHeidelberg UniversityNULLRecruiting18 YearsN/AAll40Phase 2Germany
2EUCTR2018-001387-39-DE
(EUCTR)
15/03/201930/01/2019The effect of oxygen therapy in patients with pulmonary Hypertension.A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) - SOPHA pulmonary arterial hypertension (PAH) and chronic thromboembolicpulmonary hypertension (CTEPH);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Oxygen, liquid
INN or Proposed INN: OXYGEN
Other descriptive name: Sauerstoff
Thoraxklinik-Heidelberg gGmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2Germany
3NCT03683082
(ClinicalTrials.gov)
June 5, 201820/9/2018Oxygen Treatment and Pulmonary Arterial HypertensionAcute Effects of Oxygen Supplementation Among Pulmonary Arterial Hypertension PatientsPulmonary Arterial HypertensionDrug: Oxygen supplementation;Drug: Sham O2 (medical air)George Papanicolaou HospitalNULLUnknown status18 Years80 YearsAll10N/AGreece
4NCT02661802
(ClinicalTrials.gov)
January 201220/1/2016Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger SyndromeAcute Effects of 40% Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger SyndromeEisenmenger Complex;Hypertension, PulmonaryOther: Oxygen SupplementationFederal University of São PauloNULLCompleted18 Years60 YearsBoth30N/ANULL
5NCT00626028
(ClinicalTrials.gov)
September 200420/2/2008Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator TestingComparison of Supplemental Oxygen and Nitric Oxide for Inhalation Plus Oxygen in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator TestingIdiopathic Pulmonary Arterial Hypertension;CardiomyopathyDrug: Nitric Oxide for inhalation;Drug: Oxygen;Drug: Nitric Oxide plus OxygenMallinckrodtNULLCompletedN/A18 YearsAll136Phase 3United States;France;Netherlands;Spain;United Kingdom
6NCT00317486
(ClinicalTrials.gov)
September 200321/4/2006Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyA Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyPulmonary Arterial Hypertension Related to Eisenmenger PhysiologyDrug: bosentanActelionNULLCompleted12 YearsN/ABoth54Phase 4United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom